Maxim raised the firm’s price target on Augmedix (AUGX) to $8 from $5 and keeps a Buy rating on the shares. The company’s partnership with HCA Healthcare (HCA) has the potential to increase its total addressable market by 20% given the latter’s large hospital portfolio, while its capital raise is expected to enable the company to achieve positive cash flow without additional financing, the analyst tells investors in a research note. The stock was up 89% in yesterday’s trading, closing at $3.40.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AUGX:
- Augmedix Blasts Up on New Partnership
- Augmedix price target raised to $5 from $4 at B. Riley
- Augmedix spikes 85% in pre-market after announcing pact with HCA Healthcare
- Augmedix partners with HCA Healthcare for AI-enabled documentation
- Augmedix Secures Strategic Financing from HCA Healthcare and Redmile Group